Park Place Capital Corp Takes Position in Cencora, Inc. (NYSE:COR)

Park Place Capital Corp purchased a new position in Cencora, Inc. (NYSE:COR) during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 189 shares of the company’s stock, valued at approximately $46,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of COR. Fisher Asset Management LLC acquired a new position in Cencora in the 4th quarter worth approximately $244,000. Trust Co. of Vermont purchased a new stake in Cencora in the 4th quarter worth approximately $62,000. Wahed Invest LLC purchased a new stake in Cencora in the 4th quarter worth approximately $567,000. Vanguard Group Inc. purchased a new stake in Cencora in the 4th quarter worth approximately $4,212,508,000. Finally, Hennessy Advisors Inc. purchased a new stake in Cencora in the 4th quarter worth approximately $3,307,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Trading Down 0.8 %

Shares of COR stock opened at $223.58 on Tuesday. The stock’s fifty day moving average is $228.85 and its two-hundred day moving average is $228.32. The company has a debt-to-equity ratio of 3.41, a quick ratio of 0.53 and a current ratio of 0.89. The firm has a market capitalization of $44.59 billion, a P/E ratio of 24.46, a PEG ratio of 1.57 and a beta of 0.45. Cencora, Inc. has a fifty-two week low of $171.65 and a fifty-two week high of $246.75.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, May 1st. The company reported $3.80 earnings per share for the quarter, beating analysts’ consensus estimates of $3.65 by $0.15. Cencora had a return on equity of 268.67% and a net margin of 0.67%. The company had revenue of $68.41 billion for the quarter, compared to analyst estimates of $70.60 billion. During the same quarter last year, the firm posted $3.50 EPS. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. Research analysts expect that Cencora, Inc. will post 13.44 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, May 24th. Shareholders of record on Friday, May 10th were paid a $0.51 dividend. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date was Thursday, May 9th. Cencora’s dividend payout ratio (DPR) is presently 22.32%.

Wall Street Analyst Weigh In

Several research firms have commented on COR. Citigroup upped their price objective on Cencora from $265.00 to $280.00 and gave the stock a “buy” rating in a research report on Tuesday, April 30th. StockNews.com lowered Cencora from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 2nd. SVB Leerink reiterated an “outperform” rating and set a $275.00 target price on shares of Cencora in a research report on Thursday, June 27th. Finally, Robert W. Baird increased their target price on Cencora from $275.00 to $277.00 and gave the company an “outperform” rating in a research report on Thursday, May 2nd. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $235.30.

Insiders Place Their Bets

In other Cencora news, COO Robert P. Mauch sold 57,564 shares of the firm’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $235.09, for a total value of $13,532,720.76. Following the completion of the sale, the chief operating officer now directly owns 24,412 shares of the company’s stock, valued at approximately $5,739,017.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the firm’s stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $215.12, for a total transaction of $399,991,976.80. Following the completion of the sale, the insider now directly owns 24,418,171 shares of the company’s stock, valued at approximately $5,252,836,945.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Robert P. Mauch sold 57,564 shares of the firm’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $235.09, for a total value of $13,532,720.76. Following the sale, the chief operating officer now directly owns 24,412 shares of the company’s stock, valued at $5,739,017.08. The disclosure for this sale can be found here. Insiders sold 1,956,675 shares of company stock valued at $422,352,056 in the last three months. 15.80% of the stock is currently owned by insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.